Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers

No abstract is available for this paper.

• Publication year

  1980

• Venue

  European Journal of Clinical Pharmacology

• Publication date

  1980-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/BF00625805PMID 6995131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of clofibrate and chlorophenoxy isobutyric aicd. I. Cross-over studies on human volunteers.

  2009cited by this paper
• A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate.

  1979cited by this paper
• Disposition pharmacokinetics of bezafibrate in man

  1979cited by this paper
• [Biochemical principles, therapeutic significance and prevention of drug interactions on the pharmacokinetic level].

  1979cited by this paper
• [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].

  1979cited by this paper
• A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.

  1978cited by this paper
• Clinical Pharmacokinetics of Hypolipidaemic Drugs

  1978cited by this paper
• Clofibrate kinetics after single and multiple doses

  1978cited by this paper
• [Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia].

  1978cited by this paper
• Comparison of clofibrate and bezafibrate in type IIa and type IIb hyperlipoproteinemia

  1978cited by this paper
• A gas chromatographic method for the determination of bezafibrate in serum and urine.

  1978cited by this paper
• Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia.

  1977cited by this paper
• A rapid gas chromatographic method for the determination of chlorophenoxyisobutyric acid in plasma and urine.

  1976cited by this paper
• Lack of Effect of Cholestyramine on the Pharmacokinetics of Clofibrate in Man

  1975cited by this paper

• Bezafibrate activation of PPAR drives disturbances in mitochondrial redox bioenergetics and decreases the viability of cells from patients with VLCAD deficiency.

  2021cites this paper
• Treatment Opportunities in Patients With Metabolic Myopathies

  2017cites this paper
• Bezafibrate in skeletal muscle fatty acid oxidation disorders

  2014cites this paper
• Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs.

  2012cites this paper
• Using the fish plasma model for comparative hazard identification for pharmaceuticals in the environment by extrapolation from human therapeutic data.

  2011cites this paper
• Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML)

  2010cites this paper
• PPARs as therapeutic targets for correction of inborn mitochondrial fatty acid oxidation disorders

  2008cites this paper
• Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport

  2005cites this paper
• Clinical pharmacokinetics of bezafibrate in patients with impaired renal function

  2004cites this paper
• Effects of gemfibrozil and rifampicin on the pharmacokinetics of HMG-CoA reductase inhibitors

  2004cites this paper
• Potent hypocholesterolemic activity of novel ureido phenoxyisobutyrates correlates with their intrinsic fibrate potency and not with their ACAT inhibitory activity.

  1997cites this paper
• Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.

  1996cites this paper
• Design features of a five-year Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT).

  1995cites this paper
• Modulation of cardiac intermediate filament proteins in the chick heart by fibric acid derivatives.

  1995cites this paper
• [Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 1. Single-dose administration].

  1993cites this paper
• [Comparison of the pharmacokinetics of a quick-release bezafibrate formulation with a sustained-release formulation. 2. Multiple-dose administration and chronopharmacokinetics].

  1993cites this paper
• Changes in Subcellular Accumulation of Contractile Proteins in Myocardiocyte Cultures: Effects of Fibric Acid Derivatives

  1993cites this paper
• Effects of fibrates on serum lipids and atherosclerosis.

  1988cites this paper
• Steady-state kinetics of bezafibrate retard in hyperlipidemic geriatric patients

  1988influential citation
• Circadian variation of the hypocholesterolemic effect of K13.004 in rats.

  1987cites this paper
• Lipid lowering treatment with bezafibrate in patients on chronic haemodialysis: Pharmacokinetics and effects

  1986cites this paper
• Diurnal lipid and lipoprotein profiles in hypertriglyceridemic patients with bezafibrate and clofibrate

  1986cites this paper
• Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man.

  1985cites this paper
• Sex-Related Differences in Drug Disposition in Man

  1984cites this paper
• The use of clofibrate in patients with renal insufficiency.

  1983cites this paper
• Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.

  1983cites this paper
• Pharmacokinetics of bezafibrate after single and multiple doses in the presence of renal failure

  1980cites this paper